acute lymphoblastic leukemia
Conditions
Interventions
Experimental Group:Oral Herombopag Olamine Tablets was started 1 day after the second dose of vincristine was started in the CAT+ course
Control group:The course of CAT+ was completed as planned, and no platelet elevating drugs were used for observation only
Sponsors
Affiliated Hospital of Guizhou Medical University
Eligibility
Sex/Gender
All
Age
3 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1.The patient met the diagnostic criteria for childhood acute lymphoblastic leukemia; 2.3 years old to less than 18 years old; 3.Patients with PLT > 100×10^9/L were required to complete the CAT+ phase treatment using CCCG-ALL2020 protocol; 4.The predicted survival time was >=3 months; 5.They voluntarily participated in this study, signed informed consent, and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1. During the screening period, the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were greater than 3 times the upper limit of normal values, and the levels of total bilirubin and serum creatinine were greater than 1.5 times the upper limit of normal values; 2. History of cirrhosis or portal hypertension; 3. The presence of congestive heart failure, arrhythmia, or peripheral arteriovenous thrombosis requiring medical treatment at enrollment or myocardial or cerebral infarction within 3 months before enrollment; 4. Before CAT+, oral administration of chemotherapy drugs (non-powdered) was difficult; 5. Previous allergy to the drug Haiqupopa ethanolamine; 6. Failure to complete 80% of cytarabine and mercaptopurine for various reasons (patients with definite NUDT15 or TPMT homozygous deficiency should reduce the dose of mercaptopurine by 50% before completing the dose) Other conditions considered by the investigator to be ineligible for inclusion
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Platelet transfusion volume;Minimal residual disease in bone marrow;Blood cell analysis;Coagulation function;Bleeding condition;Use of thrombopoietic drugs; | — |
Primary
| Measure | Time frame |
|---|---|
| Blood platelets; | — |
Countries
China
Contacts
Public ContactJin Jiao
Affiliated Hospital of Guizhou Medical University
Outcome results
None listed